Shalby Ltd (SHALBY) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management will allocate 80-90% of future capital to the core hospital business, signaling a strategic prioritization of its most profitable segment.
- The Gurgaon hospital is on track for cash break-even by Q4 FY27, with management stating just 20-30% more revenue growth will make it PBT positive.
- A new supply chain for the MedTech business will significantly lower costs from Q4 FY27, aiming to make the division self-sustaining and aid in group debt reduction.
Performance Overview
- The company reported broad-based growth, with faster expansion in non-orthopedic specialties like nephrology, urology, and oncology, leading to a more balanced specialty mix.
- Operational metrics improved with higher occupancy, reduced average length of stay, and an increased share of insured and government scheme patients.
- Significant operational efficiency initiatives have been implemented, with benefits from manpower outsourcing already visible and cost savings from materials and consumables expected from Q3 FY27.
- The MedTech business is focusing on quality improvements, supply chain optimization, and expanding its geographic footprint in India and internationally.
- The Delhi NCR hospital (Shalby International, Gurgaon) demonstrated a strong turnaround with 50% year-over-year revenue growth and achieved its second consecutive quarter of positive EBITDA.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.